Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial - Kaul, Martin; End, Peter; Cabanski, Maciej; Schuhler, Carole; Jakab, Annamaria; Kistowska, Magdalena; Kinhikar, Arvind; Maiolica, Alessio; Sinn, Angela; Fuhr, Rainard; Cenni, Bruno (Clinical and translational science, 2021)
Keywords: Administration, Oral; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors; Aged; Allergens; Allergies; Asthma; Asymptomatic; Atopy; Blood; Bruton's tyrosine kinase; CD63 antigen; Cross-Over Studies; Dose-Response Relationship, Drug; Drug dosages; Electrocardiography; Enzyme inhibitors; Female; Food intake; Food-Drug Interactions; Healthy Volunteers; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - adverse effects; Immunologic Factors - pharmacokinetics; Inflammation; Laboratories; Leukocytes (basophilic); Male; Mast cells; Middle Aged; Pharmacodynamics; Pharmacokinetics; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Protein-tyrosine kinase; Safety; Sjogren's syndrome; Skin; Skin Tests; Toxicity; Urticaria; Vital signs; Young Adult